Journals / Maltepe Tıp Dergisi / 2025 / Cilt: 17 Sayı: 3

The Impact of Pseudomonas aeruginosa in Sputum on the Clinical Progression of Patients with Bronchiectasis

Bronşektazi Hastalarında Balgamda Pseudomonas Aeruginosa Varlığının Klinik Gidişe Etkisi

Aslı Mezide Dulkadiroğlu(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SULTAN ABDÜLHAMİD HAN SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, GÖĞÜS HASTALIKLARI ANABİLİM DALI)0009-0009-4218-8658
Şeyma Başlılar(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SULTAN ABDÜLHAMİD HAN SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, GÖĞÜS HASTALIKLARI ANABİLİM DALI)0000-0003-1495-6508
Gökçe Külah(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SULTAN ABDÜLHAMİD HAN SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, GÖĞÜS HASTALIKLARI ANABİLİM DALI)0000-0002-9805-0537
Erhan Oğur(Özel Ereğli Anadolu Hastanesi)0000-0001-5222-2172
Bengü Şaylan(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SÜREYYAPAŞA GÖĞÜS HASTALIKLARI VE GÖĞÜS CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, GÖĞÜS HASTALIKLARI ANABİLİM DALI)0000-0002-5922-0847
Pages
72–77
Publication Date
2025-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PA growth in sputum was postively correlated with age, ICS use, use of nebulizer, BPAP, LTOT, and intensive care unit (ICU) hospitalization while negatively correlated with FEV1 (%) value. (p=0.015, p=0.048, p=0.007, p<0.001, p<0.001, p=0.02, p=0.036) Conclusion: It was concluded that the presence of PA in sputum in patients with bronchiectasis negatively affects the clinical course and respiratory function and is associated with increased mortality.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Recurrent infections and bacterial colonization of the lower respiratory tract in bronchiectasis are associated with disease progression and poor prognosis.
📊
Key Findings & Data:Materials and methods: Between October 1, 2016, and October 1, 2023, we retrospectively evaluated 220 patients diagnosed with bronchiectasis who were followed up at the chest diseases clinic and had their sputum cultures examined.
💡
Conclusion & Impact:PA growth in sputum was postively correlated with age, ICS use, use of nebulizer, BPAP, LTOT, and intensive care unit (ICU) hospitalization while negatively correlated with FEV1 (%) value. (p=0.015, p=0.048, p=0.007, p<0.001, p<0.001, p=0.02, p=0.036) Conclusion: It was concluded that the presence of PA in sputum in patients with bronchiectasis negatively affects the clinical course and respiratory function and is associated with increased mortality.
🔬Design:Araştırma Makalesi
📍Scope:2016 Verileri
⚙️Variables:Bronşektazi · Mortalite · Prognoz

Abstract

Aim: Recurrent infections and bacterial colonization of the lower respiratory tract in bronchiectasis are associated with disease progression and poor prognosis. This study aimed to investigate the impact of the existence of Pseudomonas aeruginosa (PA) in sputum on the clinical progression of patients with bronchiectasis. Materials and methods: Between October 1, 2016, and October 1, 2023, we retrospectively evaluated 220 patients diagnosed with bronchiectasis who were followed up at the chest diseases clinic and had their sputum cultures examined. Patients were divided into two groups; those with and without PA detected in the sputum (PA+ and PA -), and compared. Results: PA overgrowth was detected in 66/220 patients. Patients in PA+ group were older and used Inhaled Corticosteroids (ICS), nebulizers, Bilevel Positive Airway Pressure (BPAP), and Long-Term Oxygen Therapy (LTOT) more frequently (p= 0.024, p=0.040, p=0.010, p<0.001 and p<0.001, respectively). Pulmonary function parameters (forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC)) were lower, and intensive care unit admission and mortality rate were higher in PA+ group (p= 0.027, p= 0.036, p=0.002, p= 0.013, respectively). PA growth in sputum was postively correlated with age, ICS use, use of nebulizer, BPAP, LTOT, and intensive care unit (ICU) hospitalization while negatively correlated with FEV1 (%) value. (p=0.015, p=0.048, p=0.007, p<0.001, p<0.001, p=0.02, p=0.036) Conclusion: It was concluded that the presence of PA in sputum in patients with bronchiectasis negatively affects the clinical course and respiratory function and is associated with increased mortality.

Özet

Amaç: Bronşektazi hastalarında enfeksiyona sekonder gelişen hava yolları ve parankimal tahribat, inflamasyon ve bozulmuş klirens sonucu; bakteriyel kolonizasyon ve enfeksiyon riski artmıştır. Çalışmada bronşektazi hastalarında balgamda Pseudomonas Aeruginosa (PA) varlığının hastalığın klinik seyri üzerine etkisinin araştırılması amaçlandı. Gereç ve yöntem: 1 Ekim 2016 ile 1 Ekim 2023 tarihleri arasında göğüs hastalıkları kliniğinde bronşektazi tanısı ile takip edilen ve balgam kültürü çalışılmış olan 220 hasta retrospektif olarak değerlendirildi. Hastalar balgamda PA saptanan ve saptanmayan şeklinde ikiye ayrılarak karşılaştırma yapıldı. Bulgular: PA üremesi olanların daha ileri yaşta olduğu ve bu hastalarda İnhale Kortikosteroid (İKS), nebülizatör, Bilevel Pozitif Havayolu Basıncı (BPAP), Uzun Süreli Oksijen Tedavisi (USOT) kullanımının daha fazla olduğu saptandı. Solunum fonksiyon parametrelerinin daha düşük olduğu ve yoğun bakım yatışı ile mortalitenin daha sık olduğu saptandı. PA üremesi ile yaş, İKS, solunum destek cihazı kullanımı ve yoğun bakım yatışı arasında pozitif; PA üremesi ile FEV1 değerleri arasında negatif korelasyon saptandı. Sonuç: Bronşektazi hastalarında balgamda PA saptanmasının klinik seyir ve solunum fonksiyonlarını olumsuz etkilediği sonucuna varıldı.

🔖

Cite This Article

Dulkadiroğlu, A. M., Başlılar, Ş., Külah, G., Oğur, E., Şaylan, B. (2025). The Impact of Pseudomonas aeruginosa in Sputum on the Clinical Progression of Patients with Bronchiectasis. Maltepe Tıp Dergisi, Cilt: 17 Sayı: 3, 72–77. https://doi.org/10.35514/mtd.2025.132

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Referans1 Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
  2. Referans2 Song J, Sin S, Kang HR, Oh YM, Jeong I, Kim Y, et al. Clinical impacts of Pseudomonas aeruginosa isolation in patients with bronchiectasis: findings from the KMBARC registry. J Clin Med. 2024;13(17):5312.
  3. Referans3 Chai YH, Xu JF. How does Pseudomonas aeruginosa affect the progression of bronchiectasis? Clin Microbiol Infect. 2020;26(3):313–318.
  4. Referans4 Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649–662.
  5. Referans5 Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–1611.
  6. Referans6 Gao YH, Guan WJ, Zhu YN, Chen RC, Zhang GJ. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. Int J Chron Obstruct Pulmon Dis. 2018;13:237–246.
  7. Referans7 Bulbul Y, Ercen Diken O, Ugur Chousein E, et al. Bronchiectasis in Turkey: under the light of national publications [Article in Turkish]. Tuberk Toraks. 2020;68(1):48–65.
  8. Referans8 Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974–979.
  9. Referans9 Thng KX, Tiew PY, Mac Aogain M, Narayana JK, Jaggi TK, Ivan FX, et al. Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study. Eur Respir J. 2025;66(2):240321.
  10. Referans10 Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax. 2012;67(11):1006–1013.
  11. Referans11 Chalmers JD, Haworth CS, Flume P, Long MB, Burgel PR, Dimakou K, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur Respir J. 2025;65(1):240185.
  12. Referans12 Kwok WC, Lau KK, Teo KC, Ho JCM. Correlation of sputum inflammatory markers with severity and blood inflammatory markers in bronchiectasis. J Thorac Dis. 2024;16(8):5190–5200.
  13. Referans 13 Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL. Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications. Respir Res. 2021;22(1):132.
  14. Referans14 Pieters A, Bakker M, Hoek RAS, Altenburg J, van Westreenen M, Aerts J, et al. Predicting factors for chronic colonization of Pseudomonas aeruginosa in bronchiectasis. Eur J Clin Microbiol Infect Dis. 2019;38(12):2299–2304.